カテゴリ： 世界, 医療/バイオ, Market Monitor Global

性腺機能低下症治療薬のグローバル市場展望 2023年-2029年：注射剤、カプセル剤

■ 英語タイトル：Hypogonadism Drug Market, Global Outlook and Forecast 2023-2029

調査会社Market Monitor Global社が発行したリサーチレポート（データ管理コード：MMG23LY8791）■ 発行会社/調査会社：Market Monitor Global
■ 商品コード：MMG23LY8791
■ 発行日：2023年7月
■ 調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
■ 産業分野：医薬品＆ヘルスケア
■ ページ数：118
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥494,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥642,200見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥741,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Market Monitor Global社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[性腺機能低下症治療薬のグローバル市場展望 2023年-2029年：注射剤、カプセル剤]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査レポートは次の情報を含め、世界の性腺機能低下症治療薬市場規模と予測を収録しています。・世界の性腺機能低下症治療薬市場：売上、2018年-2023年、2024年-2029年
・世界の性腺機能低下症治療薬市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の性腺機能低下症治療薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「注射剤」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

性腺機能低下症治療薬のグローバル主要企業は、Allergan、 AbbVie、 Endo Pharmaceuticals、 Pfizer Inc.、 Clarus Therapeutics, Inc.、 Aytu BioScience, Inc.、 Antares Pharma、 Upsher-Smith Laboratories, Inc.、 Beijing Shuanghe Pharmaceutical Co., Ltd、 Tianjin Jinyao Amino Acid Co., Ltd、 Shanghai General Pharmaceutical Co., Ltd、 Tianjin Lisheng Pharmaceutical Co., Ltd、 Chengde Jiulong Pharmaceutical Co., Ltd、 Harbin Pharmaceutical Group、 Shenyang Keda Pharmaceutical Co., Ltd、 Zhejiang Xianju Pharmaceutical Co., Ltdなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、性腺機能低下症治療薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の性腺機能低下症治療薬市場：タイプ別、2018年-2023年、2024年-2029年
世界の性腺機能低下症治療薬市場：タイプ別市場シェア、2022年
・注射剤、カプセル剤

世界の性腺機能低下症治療薬市場：用途別、2018年-2023年、2024年-2029年
世界の性腺機能低下症治療薬市場：用途別市場シェア、2022年
・病院、薬局、専門クリニック

世界の性腺機能低下症治療薬市場：地域・国別、2018年-2023年、2024年-2029年
世界の性腺機能低下症治療薬市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における性腺機能低下症治療薬のグローバル売上、2018年-2023年
・主要企業における性腺機能低下症治療薬のグローバル売上シェア、2022年
・主要企業における性腺機能低下症治療薬のグローバル販売量、2018年-2023年
・主要企業における性腺機能低下症治療薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Allergan、 AbbVie、 Endo Pharmaceuticals、 Pfizer Inc.、 Clarus Therapeutics, Inc.、 Aytu BioScience, Inc.、 Antares Pharma、 Upsher-Smith Laboratories, Inc.、 Beijing Shuanghe Pharmaceutical Co., Ltd、 Tianjin Jinyao Amino Acid Co., Ltd、 Shanghai General Pharmaceutical Co., Ltd、 Tianjin Lisheng Pharmaceutical Co., Ltd、 Chengde Jiulong Pharmaceutical Co., Ltd、 Harbin Pharmaceutical Group、 Shenyang Keda Pharmaceutical Co., Ltd、 Zhejiang Xianju Pharmaceutical Co., Ltd

*************************************************************

・調査・分析レポートの概要
性腺機能低下症治療薬市場の定義
市場セグメント
世界の性腺機能低下症治療薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の性腺機能低下症治療薬市場規模
世界の性腺機能低下症治療薬市場規模：2022年 VS 2029年
世界の性腺機能低下症治療薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの性腺機能低下症治療薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の性腺機能低下症治療薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：注射剤、カプセル剤
性腺機能低下症治療薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院、薬局、専門クリニック
性腺機能低下症治療薬の用途別グローバル売上・予測

・地域別市場分析
地域別性腺機能低下症治療薬市場規模 2022年と2029年
地域別性腺機能低下症治療薬売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
Allergan、 AbbVie、 Endo Pharmaceuticals、 Pfizer Inc.、 Clarus Therapeutics, Inc.、 Aytu BioScience, Inc.、 Antares Pharma、 Upsher-Smith Laboratories, Inc.、 Beijing Shuanghe Pharmaceutical Co., Ltd、 Tianjin Jinyao Amino Acid Co., Ltd、 Shanghai General Pharmaceutical Co., Ltd、 Tianjin Lisheng Pharmaceutical Co., Ltd、 Chengde Jiulong Pharmaceutical Co., Ltd、 Harbin Pharmaceutical Group、 Shenyang Keda Pharmaceutical Co., Ltd、 Zhejiang Xianju Pharmaceutical Co., Ltd
...

There are two drugs for treatment of hypogonadism, one is testosterone replacement therapy drug; The other is used for gonadotropin treatment, which aims to maintain the normal development of male secondary sexual characteristics and restore fertility.
This report aims to provide a comprehensive presentation of the global market for Hypogonadism Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hypogonadism Drug. This report contains market size and forecasts of Hypogonadism Drug in global, including the following market information:
Global Hypogonadism Drug Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Hypogonadism Drug Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Hypogonadism Drug companies in 2022 (%)
The global Hypogonadism Drug market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Injection Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Hypogonadism Drug include Allergan, AbbVie, Endo Pharmaceuticals, Pfizer Inc., Clarus Therapeutics, Inc., Aytu BioScience, Inc., Antares Pharma, Upsher-Smith Laboratories, Inc. and Beijing Shuanghe Pharmaceutical Co., Ltd, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Hypogonadism Drug manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hypogonadism Drug Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Hypogonadism Drug Market Segment Percentages, by Type, 2022 (%)
Injection
Capsule
Global Hypogonadism Drug Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Hypogonadism Drug Market Segment Percentages, by Application, 2022 (%)
Hospital
Pharmacy
Specialist Clinic
Global Hypogonadism Drug Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Hypogonadism Drug Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hypogonadism Drug revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Hypogonadism Drug revenues share in global market, 2022 (%)
Key companies Hypogonadism Drug sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Hypogonadism Drug sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Allergan
AbbVie
Endo Pharmaceuticals
Pfizer Inc.
Clarus Therapeutics, Inc.
Aytu BioScience, Inc.
Antares Pharma
Upsher-Smith Laboratories, Inc.
Beijing Shuanghe Pharmaceutical Co., Ltd
Tianjin Jinyao Amino Acid Co., Ltd
Shanghai General Pharmaceutical Co., Ltd
Tianjin Lisheng Pharmaceutical Co., Ltd
Chengde Jiulong Pharmaceutical Co., Ltd
Harbin Pharmaceutical Group
Shenyang Keda Pharmaceutical Co., Ltd
Zhejiang Xianju Pharmaceutical Co., Ltd
Outline of Major Chapters:
Chapter 1: Introduces the definition of Hypogonadism Drug, market overview.
Chapter 2: Global Hypogonadism Drug market size in revenue and volume.
Chapter 3: Detailed analysis of Hypogonadism Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Hypogonadism Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Hypogonadism Drug capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

*** レポート目次（コンテンツ）***

1 Introduction to Research & Analysis Reports
1.1 Hypogonadism Drug Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Hypogonadism Drug Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Hypogonadism Drug Overall Market Size
2.1 Global Hypogonadism Drug Market Size: 2022 VS 2029
2.2 Global Hypogonadism Drug Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Hypogonadism Drug Sales: 2018-2029
3 Company Landscape
3.1 Top Hypogonadism Drug Players in Global Market
3.2 Top Global Hypogonadism Drug Companies Ranked by Revenue
3.3 Global Hypogonadism Drug Revenue by Companies
3.4 Global Hypogonadism Drug Sales by Companies
3.5 Global Hypogonadism Drug Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Hypogonadism Drug Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Hypogonadism Drug Product Type
3.8 Tier 1, Tier 2 and Tier 3 Hypogonadism Drug Players in Global Market
3.8.1 List of Global Tier 1 Hypogonadism Drug Companies
3.8.2 List of Global Tier 2 and Tier 3 Hypogonadism Drug Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Hypogonadism Drug Market Size Markets, 2022 & 2029
4.1.2 Injection
4.1.3 Capsule
4.2 By Type – Global Hypogonadism Drug Revenue & Forecasts
4.2.1 By Type – Global Hypogonadism Drug Revenue, 2018-2023
4.2.2 By Type – Global Hypogonadism Drug Revenue, 2024-2029
4.2.3 By Type – Global Hypogonadism Drug Revenue Market Share, 2018-2029
4.3 By Type – Global Hypogonadism Drug Sales & Forecasts
4.3.1 By Type – Global Hypogonadism Drug Sales, 2018-2023
4.3.2 By Type – Global Hypogonadism Drug Sales, 2024-2029
4.3.3 By Type – Global Hypogonadism Drug Sales Market Share, 2018-2029
4.4 By Type – Global Hypogonadism Drug Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Hypogonadism Drug Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Pharmacy
5.1.4 Specialist Clinic
5.2 By Application – Global Hypogonadism Drug Revenue & Forecasts
5.2.1 By Application – Global Hypogonadism Drug Revenue, 2018-2023
5.2.2 By Application – Global Hypogonadism Drug Revenue, 2024-2029
5.2.3 By Application – Global Hypogonadism Drug Revenue Market Share, 2018-2029
5.3 By Application – Global Hypogonadism Drug Sales & Forecasts
5.3.1 By Application – Global Hypogonadism Drug Sales, 2018-2023
5.3.2 By Application – Global Hypogonadism Drug Sales, 2024-2029
5.3.3 By Application – Global Hypogonadism Drug Sales Market Share, 2018-2029
5.4 By Application – Global Hypogonadism Drug Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Hypogonadism Drug Market Size, 2022 & 2029
6.2 By Region – Global Hypogonadism Drug Revenue & Forecasts
6.2.1 By Region – Global Hypogonadism Drug Revenue, 2018-2023
6.2.2 By Region – Global Hypogonadism Drug Revenue, 2024-2029
6.2.3 By Region – Global Hypogonadism Drug Revenue Market Share, 2018-2029
6.3 By Region – Global Hypogonadism Drug Sales & Forecasts
6.3.1 By Region – Global Hypogonadism Drug Sales, 2018-2023
6.3.2 By Region – Global Hypogonadism Drug Sales, 2024-2029
6.3.3 By Region – Global Hypogonadism Drug Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Hypogonadism Drug Revenue, 2018-2029
6.4.2 By Country – North America Hypogonadism Drug Sales, 2018-2029
6.4.3 US Hypogonadism Drug Market Size, 2018-2029
6.4.4 Canada Hypogonadism Drug Market Size, 2018-2029
6.4.5 Mexico Hypogonadism Drug Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Hypogonadism Drug Revenue, 2018-2029
6.5.2 By Country – Europe Hypogonadism Drug Sales, 2018-2029
6.5.3 Germany Hypogonadism Drug Market Size, 2018-2029
6.5.4 France Hypogonadism Drug Market Size, 2018-2029
6.5.5 U.K. Hypogonadism Drug Market Size, 2018-2029
6.5.6 Italy Hypogonadism Drug Market Size, 2018-2029
6.5.7 Russia Hypogonadism Drug Market Size, 2018-2029
6.5.8 Nordic Countries Hypogonadism Drug Market Size, 2018-2029
6.5.9 Benelux Hypogonadism Drug Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Hypogonadism Drug Revenue, 2018-2029
6.6.2 By Region – Asia Hypogonadism Drug Sales, 2018-2029
6.6.3 China Hypogonadism Drug Market Size, 2018-2029
6.6.4 Japan Hypogonadism Drug Market Size, 2018-2029
6.6.5 South Korea Hypogonadism Drug Market Size, 2018-2029
6.6.6 Southeast Asia Hypogonadism Drug Market Size, 2018-2029
6.6.7 India Hypogonadism Drug Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Hypogonadism Drug Revenue, 2018-2029
6.7.2 By Country – South America Hypogonadism Drug Sales, 2018-2029
6.7.3 Brazil Hypogonadism Drug Market Size, 2018-2029
6.7.4 Argentina Hypogonadism Drug Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Hypogonadism Drug Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Hypogonadism Drug Sales, 2018-2029
6.8.3 Turkey Hypogonadism Drug Market Size, 2018-2029
6.8.4 Israel Hypogonadism Drug Market Size, 2018-2029
6.8.5 Saudi Arabia Hypogonadism Drug Market Size, 2018-2029
6.8.6 UAE Hypogonadism Drug Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Allergan
7.1.1 Allergan Company Summary
7.1.2 Allergan Business Overview
7.1.3 Allergan Hypogonadism Drug Major Product Offerings
7.1.4 Allergan Hypogonadism Drug Sales and Revenue in Global (2018-2023)
7.1.5 Allergan Key News & Latest Developments
7.2 AbbVie
7.2.1 AbbVie Company Summary
7.2.2 AbbVie Business Overview
7.2.3 AbbVie Hypogonadism Drug Major Product Offerings
7.2.4 AbbVie Hypogonadism Drug Sales and Revenue in Global (2018-2023)
7.2.5 AbbVie Key News & Latest Developments
7.3 Endo Pharmaceuticals
7.3.1 Endo Pharmaceuticals Company Summary
7.3.2 Endo Pharmaceuticals Business Overview
7.3.3 Endo Pharmaceuticals Hypogonadism Drug Major Product Offerings
7.3.4 Endo Pharmaceuticals Hypogonadism Drug Sales and Revenue in Global (2018-2023)
7.3.5 Endo Pharmaceuticals Key News & Latest Developments
7.4 Pfizer Inc.
7.4.1 Pfizer Inc. Company Summary
7.4.2 Pfizer Inc. Business Overview
7.4.3 Pfizer Inc. Hypogonadism Drug Major Product Offerings
7.4.4 Pfizer Inc. Hypogonadism Drug Sales and Revenue in Global (2018-2023)
7.4.5 Pfizer Inc. Key News & Latest Developments
7.5 Clarus Therapeutics, Inc.
7.5.1 Clarus Therapeutics, Inc. Company Summary
7.5.2 Clarus Therapeutics, Inc. Business Overview
7.5.3 Clarus Therapeutics, Inc. Hypogonadism Drug Major Product Offerings
7.5.4 Clarus Therapeutics, Inc. Hypogonadism Drug Sales and Revenue in Global (2018-2023)
7.5.5 Clarus Therapeutics, Inc. Key News & Latest Developments
7.6 Aytu BioScience, Inc.
7.6.1 Aytu BioScience, Inc. Company Summary
7.6.2 Aytu BioScience, Inc. Business Overview
7.6.3 Aytu BioScience, Inc. Hypogonadism Drug Major Product Offerings
7.6.4 Aytu BioScience, Inc. Hypogonadism Drug Sales and Revenue in Global (2018-2023)
7.6.5 Aytu BioScience, Inc. Key News & Latest Developments
7.7 Antares Pharma
7.7.1 Antares Pharma Company Summary
7.7.2 Antares Pharma Business Overview
7.7.3 Antares Pharma Hypogonadism Drug Major Product Offerings
7.7.4 Antares Pharma Hypogonadism Drug Sales and Revenue in Global (2018-2023)
7.7.5 Antares Pharma Key News & Latest Developments
7.8 Upsher-Smith Laboratories, Inc.
7.8.1 Upsher-Smith Laboratories, Inc. Company Summary
7.8.2 Upsher-Smith Laboratories, Inc. Business Overview
7.8.3 Upsher-Smith Laboratories, Inc. Hypogonadism Drug Major Product Offerings
7.8.4 Upsher-Smith Laboratories, Inc. Hypogonadism Drug Sales and Revenue in Global (2018-2023)
7.8.5 Upsher-Smith Laboratories, Inc. Key News & Latest Developments
7.9 Beijing Shuanghe Pharmaceutical Co., Ltd
7.9.1 Beijing Shuanghe Pharmaceutical Co., Ltd Company Summary
7.9.2 Beijing Shuanghe Pharmaceutical Co., Ltd Business Overview
7.9.3 Beijing Shuanghe Pharmaceutical Co., Ltd Hypogonadism Drug Major Product Offerings
7.9.4 Beijing Shuanghe Pharmaceutical Co., Ltd Hypogonadism Drug Sales and Revenue in Global (2018-2023)
7.9.5 Beijing Shuanghe Pharmaceutical Co., Ltd Key News & Latest Developments
7.10 Tianjin Jinyao Amino Acid Co., Ltd
7.10.1 Tianjin Jinyao Amino Acid Co., Ltd Company Summary
7.10.2 Tianjin Jinyao Amino Acid Co., Ltd Business Overview
7.10.3 Tianjin Jinyao Amino Acid Co., Ltd Hypogonadism Drug Major Product Offerings
7.10.4 Tianjin Jinyao Amino Acid Co., Ltd Hypogonadism Drug Sales and Revenue in Global (2018-2023)
7.10.5 Tianjin Jinyao Amino Acid Co., Ltd Key News & Latest Developments
7.11 Shanghai General Pharmaceutical Co., Ltd
7.11.1 Shanghai General Pharmaceutical Co., Ltd Company Summary
7.11.2 Shanghai General Pharmaceutical Co., Ltd Hypogonadism Drug Business Overview
7.11.3 Shanghai General Pharmaceutical Co., Ltd Hypogonadism Drug Major Product Offerings
7.11.4 Shanghai General Pharmaceutical Co., Ltd Hypogonadism Drug Sales and Revenue in Global (2018-2023)
7.11.5 Shanghai General Pharmaceutical Co., Ltd Key News & Latest Developments
7.12 Tianjin Lisheng Pharmaceutical Co., Ltd
7.12.1 Tianjin Lisheng Pharmaceutical Co., Ltd Company Summary
7.12.2 Tianjin Lisheng Pharmaceutical Co., Ltd Hypogonadism Drug Business Overview
7.12.3 Tianjin Lisheng Pharmaceutical Co., Ltd Hypogonadism Drug Major Product Offerings
7.12.4 Tianjin Lisheng Pharmaceutical Co., Ltd Hypogonadism Drug Sales and Revenue in Global (2018-2023)
7.12.5 Tianjin Lisheng Pharmaceutical Co., Ltd Key News & Latest Developments
7.13 Chengde Jiulong Pharmaceutical Co., Ltd
7.13.1 Chengde Jiulong Pharmaceutical Co., Ltd Company Summary
7.13.2 Chengde Jiulong Pharmaceutical Co., Ltd Hypogonadism Drug Business Overview
7.13.3 Chengde Jiulong Pharmaceutical Co., Ltd Hypogonadism Drug Major Product Offerings
7.13.4 Chengde Jiulong Pharmaceutical Co., Ltd Hypogonadism Drug Sales and Revenue in Global (2018-2023)
7.13.5 Chengde Jiulong Pharmaceutical Co., Ltd Key News & Latest Developments
7.14 Harbin Pharmaceutical Group
7.14.1 Harbin Pharmaceutical Group Company Summary
7.14.2 Harbin Pharmaceutical Group Business Overview
7.14.3 Harbin Pharmaceutical Group Hypogonadism Drug Major Product Offerings
7.14.4 Harbin Pharmaceutical Group Hypogonadism Drug Sales and Revenue in Global (2018-2023)
7.14.5 Harbin Pharmaceutical Group Key News & Latest Developments
7.15 Shenyang Keda Pharmaceutical Co., Ltd
7.15.1 Shenyang Keda Pharmaceutical Co., Ltd Company Summary
7.15.2 Shenyang Keda Pharmaceutical Co., Ltd Business Overview
7.15.3 Shenyang Keda Pharmaceutical Co., Ltd Hypogonadism Drug Major Product Offerings
7.15.4 Shenyang Keda Pharmaceutical Co., Ltd Hypogonadism Drug Sales and Revenue in Global (2018-2023)
7.15.5 Shenyang Keda Pharmaceutical Co., Ltd Key News & Latest Developments
7.16 Zhejiang Xianju Pharmaceutical Co., Ltd
7.16.1 Zhejiang Xianju Pharmaceutical Co., Ltd Company Summary
7.16.2 Zhejiang Xianju Pharmaceutical Co., Ltd Business Overview
7.16.3 Zhejiang Xianju Pharmaceutical Co., Ltd Hypogonadism Drug Major Product Offerings
7.16.4 Zhejiang Xianju Pharmaceutical Co., Ltd Hypogonadism Drug Sales and Revenue in Global (2018-2023)
7.16.5 Zhejiang Xianju Pharmaceutical Co., Ltd Key News & Latest Developments
8 Global Hypogonadism Drug Production Capacity, Analysis
8.1 Global Hypogonadism Drug Production Capacity, 2018-2029
8.2 Hypogonadism Drug Production Capacity of Key Manufacturers in Global Market
8.3 Global Hypogonadism Drug Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Hypogonadism Drug Supply Chain Analysis
10.1 Hypogonadism Drug Industry Value Chain
10.2 Hypogonadism Drug Upstream Market
10.3 Hypogonadism Drug Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Hypogonadism Drug Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 細気管支炎治療のグローバル市場展望 2023年-2029年：錠剤/カプセル剤、注射剤、その他
  • 藿香正気散のグローバル市場展望 2023年-2029年：丸剤、カプセル剤、ソフトカプセル、内服液、その他
  • 六味地黄丸のグローバル市場展望 2023年-2029年：丸剤、カプセル剤、ソフトカプセル剤、その他
  • 六味丸の世界市場2023年：丸剤、カプセル剤、ソフトカプセル剤、その他
  • 慢性疲労症候群治療薬のグローバル市場展望 2023年-2029年：鎮痛剤・NSAID、抗うつ薬・抗精神病薬、抗菌薬・免疫調節薬
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(MMG23LY8791 )"性腺機能低下症治療薬のグローバル市場展望 2023年-2029年：注射剤、カプセル剤" (英文：Hypogonadism Drug Market, Global Outlook and Forecast 2023-2029)はMarket Monitor Global社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。